Context

Valneva is a French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

The company has been listed on Euronext Paris since 2007 and on Nasdaq since 2021. The Company has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease and the chikungunya virus.

Proceeds will be mainly used to fund the development of the Lyme vaccine candidate through completion of Phase 3 initiated in August 2022, the chikungunya vaccine candidate through BLA approval by the end of 2022, and for working capital and general corporate purposes.

About Valneva

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease and the chikungunya virus.

Discover Valneva

Hervé Ronin

Investment Banking

Hervé Ronin photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Théodore De Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Jonathan Pavillard

Investment Banking

Jonathan Pavillard

Hugo Fischer

Equity Capital Markets

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center